23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 4 (OX40; TNFRSF4; CD134)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest agonizing OX40 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an agonist anti-OX40 antibody delayed disease onset and decreased the number of...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Merck, GlaxoSmithKline deal

The companies partnered to conduct a U.S. Phase I trial to evaluate Merck’s Keytruda pembrolizumab with GlaxoSmithKline’s GSK3174998 to treat patients with locally advanced, recurrent or metastatic solid tumors that have progressed after...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

GSK3174998: Phase I started

GlaxoSmithKline began an open-label, U.S. Phase I trial to evaluate 0.003-10 mg/kg IV GSK3174998 every 3 weeks for up to 48 weeks alone or with IV Keytruda pembrolizumab in about 264 patients. The first...
02:15 , Nov 4, 2015 |  BC Extra  |  Company News

GSK aims for 20 filings by 2020

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said at its R&D day Tuesday that it hopes to submit up to 20 pipeline candidates for approval by 2020, with an additional 20 filings to follow in 2021-25. GSK highlighted...